Assembly Biosciences
Christina Schmidt, MBA, RAC, is an accomplished professional in regulatory affairs with extensive experience at Assembly Biosciences, Inc. since July 2017, where roles have included Sr. Director, Director, Associate Director, and Sr. Manager of Regulatory Affairs. Prior experience includes a tenure at Gilead Sciences from August 2003 to July 2017, serving in various capacities related to drug substance regulatory strategy and process chemistry. Christina holds a Master of Business Administration from Golden Gate University and a Regulatory Affairs Certificate from UC Berkeley Extension, as well as a Bachelor's degree in Chemistry from the University of California, Berkeley.
This person is not in any teams
This person is not in any offices
Assembly Biosciences
9 followers
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.